Sanjay Popat, MBBS, FRCP, PhD, discusses the investigation of lurbinectedin as a second-line treatment for patients with small cell lung cancer.
Sanjay Popat, PhD, FRCP, The Royal Marsden Hospital
Advertisement
Articles by Sanjay Popat, PhD, FRCP, The Royal Marsden Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses the clinical implications of the final results of the phase 3 ALTA-1L trial in ALK-positive non–small cell lung cancer. Scroll to 0:07 in the video for Dr. Popat's topline points on the data.
Advertisement
Latest Updated Articles
Dr. Popat on the Clinical Implications of the Final Results of the ALTA-1L Trial in ALK+ NSCLCPublished: October 4th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5